title: ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology.
abstract: Comprehensive molecular genotyping of lung cancers has become a key requirement for guiding therapeutic decisions. As a paradigm model of implementing next-generation comprehensive diagnostics, Network Genomic Medicine (NGM) has established central diagnostic and clinical trial platforms for centralised testing and decentralised personalised treatment in clinical practice. Here, we describe the structures of the NGM network and give a summary of technologies to identify patients with anaplastic lymphoma kinase (ALK) fusion-positive lung adenocarcinomas. As unifying test platforms will become increasingly important for delivering reliable, quick and affordable tests, the NGM diagnostic platform is currently implementing a comprehensive hybrid capture-based parallel sequencing pan-cancer assay.
authors: Institute of Pathology, University Hospital Cologne, Cologne Network Genomic Medicine, Cologne carina.heydt@uk-koeln.de.
authors: C
authors: C
authors: Heydt
authors: Institute of Pathology, University Hospital Cologne, Cologne Network Genomic Medicine, Cologne Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
authors: A
authors: A
authors: Kostenko
authors: Institute of Pathology, University Hospital Cologne, Cologne Network Genomic Medicine, Cologne.
authors: S
authors: S
authors: Merkelbach-Bruse
authors: Network Genomic Medicine, Cologne Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
authors: J
authors: J
authors: Wolf
authors: Institute of Pathology, University Hospital Cologne, Cologne Network Genomic Medicine, Cologne.
authors: R
authors: R
authors: Büttner
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000201:enzymology* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000077548:Anaplastic Lymphoma Kinase; D000818:Animals; D015321:Gene Rearrangement; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000175:diagnosis / Q000201:enzymology* / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D057285:Precision Medicine; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: anaplastic lymphoma kinase; fluorescence in situ hybridisation; hybrid capture-based parallel sequencing; immunohistochemistry; network genomic medicine; parallel sequencing